Binding site elucidation and structure guided design of macrocyclic IL-17A antagonists.

ABSTRACT: Interleukin-17A (IL-17A) is a principal driver of multiple inflammatory and immune disorders. Antibodies that neutralize IL-17A or its receptor (IL-17RA) deliver efficacy in autoimmune diseases, but no small-molecule IL-17A antagonists have yet progressed into clinical trials. Investigation of a series of linear peptide ligands to IL-17A and characterization of their binding site has enabled the design of novel macrocyclic ligands that are themselves potent IL-17A antagonists.

SUBMITTER: Liu S 

PROVIDER: S-EPMC4985813 | biostudies-literature | 2016 Aug

REPOSITORIES: biostudies-literature